A new two-pager about the 340B program by drug industry consultant Berkeley Research Group (BRG) indicates it was created for the 340B Industry Roundtable—an apparently new 340B drug industry stakeholder group.
The infographic came to light Sunday. It includes
…
Drug manufacturer Lilly will let 340B covered entities buy medicines for shipment to an unlimited number of contract pharmacies if entities agree to provide claims-level data associated with such orders, a company spokesperson said late today.
340B hospitals and health
…
Drug manufacturer Johnson & Johnson’s decision to end voluntary 340B drug discounts on orphan drugs to more than 1,000 rural hospitals at the end of this year “will make it even harder for patients to access drugs they desperately need,”
…
Three drug manufacturers recently announced they are refunding 340B overpayments to covered entities, part of a growing number of companies that have disclosed they miscalculated the pricing of their products.
The U.S. Health Resources and Services Administration posted GlaxoSmithKline,
…
Drug manufacturer Johnson & Johnson will stop offering voluntary 340B pricing on Janssen brand orphan drugs to hundreds of rural hospitals at the end of this year. J&J’s decision also applies to the three free-standing cancer hospitals enrolled in 340B.
…
UPDATED Wednesday Dec. 1, 2021, 1:15 p.m. EST—Includes comments from Amgen, HRSA, and hospital group 340B Health.
Biopharmaceutical manufacturer Amgen this morning became the 10th pharmaceutical company to announce conditions on 340B pricing when contract pharmacies dispense medicines to
…
Drug manufacturer Clovis Oncology has decided for now not to implement drug discount management company Kalderos’ 340B Pay service to let drug companies pay 340B ceiling prices as back-end rebates instead of as front-end discounts, Kalderos said late yesterday.
“We
…
Belgian-based pharmaceutical manufacturer UCB this morning became the ninth drug company to impose limits on 340B pricing involving contract pharmacies.
Hospitals reported getting letters and an FAQ from UCB today by email announcing that, effective Dec. 13 and with
…
Drug distributor AmerisourceBergen’s business consulting unit Xcenda has written an issue brief for drug industry-led group AIR340B saying Congress and the executive branch should revise 340B eligibility standards to keep 340B “from being used solely as a profit center for
…
×
*Sign up for news summaries and alerts from 340B Report